The Psychedelic Therapy Advisory Working Group has been formed for the purpose of reviewing existing research on the cost-benefit profile of the use of psychedelics to improve mental health and to make findings and recommendations regarding the advisability of the establishment of a State program to permit health care providers to administer psychedelics in a therapeutic setting and the impact on public health of allowing individuals to legally access psychedelics under State law.
Meetings
September 9, 2024
August 13, 2024
July 9, 2024
For more information about the Psychedelic Therapy Advisory Working Group please contact Kelley Klein at Kelley.Klein@partner.vermont.gov.